降低乳腺癌风险的策略已得到充分验证，但高风险人群采用这些策略仍然存在障碍。我们在患有乳腺癌高风险的参与者中进行了一项研究，以验证虚拟乳房健康决策工具是否会影响参与者开始降低风险活动的意愿，确定采用这些策略的障碍，并了解它是否会影响乳腺癌焦虑。研究样本为根据风险测量进行筛查的女性 (WISDOM) 临床试验个性化（研究）部门的 318 名参与者。在审查该工具后，这些参与者完成了反馈调查。我们证明，15 名 (4.7%) 女性正在采取降低内分泌风险的措施，123 名 (38.7%) 女性正在减少酒精摄入量，199 名 (62.6%) 女性正在锻炼身体。在对 109 名受访者进行的为期三个月的跟踪调查中，61 名考虑降低内分泌风险的女性中，只有 8 名（13.1%）进行了追求。相比之下，16 名考虑减少饮酒的参与者中有 11 名 (68%) 参加了这项活动，24 名考虑锻炼的女性中有 14 名 (58%) 参加了这项活动。参与者将对副作用的恐惧列为降低内分泌风险的最常见障碍。我们还提出了提高乳房健康决策工具有效性的进一步措施。© 2024。作者。

Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual breast health decision tool impacted a participant's willingness to start risk-reducing activities, identify barriers to adopting these strategies, and understand if it affects breast cancer anxiety. The study sample was 318 participants in the personalized (investigational) arm of the Women Informed to Screen Depending on Measures of risk (WISDOM) clinical trial. After reviewing the tool, these participants completed a feedback survey. We demonstrated that 15 (4.7%) women were taking endocrine risk reduction, 123 (38.7%) were reducing alcohol intake, and 199 (62.6%) were exercising. In the three-month follow-up survey of 109 respondents, only 8 of 61 (13.1%) women who considered endocrine risk reduction pursued it. In contrast, 11 of 16 (68%) participants who considered alcohol reduction pursued the activity, and 14 of 24 (58%) women who considered exercise followed through. Participants listed fear of side effects as the most common barrier to endocrine risk reduction. We also present further steps to be taken to improve the effectiveness of the Breast Health Decisions tool.© 2024. The Author(s).